ISTANBUL escrs

Enhancement of pseudophakic refractive errors with sulcus-fixated supplementary IOLs after 5 years.

Session Details

Session Title: Cataract 2
Session Date/Time: Saturday 21/02/2015 | 08:30-11:00
Paper Time: 10:36
Venue: Hall 1
First Author: : G.Kahraman AUSTRIA
Co Author(s): :    M. Amon   F. Prager           

Abstract Details

Purpose:

To present clinical results of a recently introduced, hydrophilic acrylic, foldable, single piece, sulcus-fixated supplementary posterior chamber intraocular lens (Sulcoflex®, Rayner ltd. East Sussex, UK) after 5 years of follow-up

Setting:

Academic Teaching Hospital of St. John, Vienna, Austria Department of Ophthalmology

Methods:

This prospective, non-randomised, study included 47 eyes that received a secondary intraocular lens (Sulcoflex 653L®) to correct residual refractive error post cataract surgery. Clinical and refractive outcomes were evaluated. All IOLs were implanted with an injector through a 2.75 mm clear cornea incision in the ciliary sulcus. Postoperative examinations were performed after 1, 6 months and after 3 and 5 years. The study protocol included the assessment of visual acuity (UCVA, BCVA), specular microscopy and scheimpflug photography.

Results:

Surgeries were performed without any complication in all cases; Mean Follow up was 29 months (range 12 to 84 months). No intra- or postoperative complications were detected. The postoperative refraction remained stabile at all visits. The refraction of 45 eyes (96.6 % ) were within ±0.50 Diopters. IOP was within the normal range at all visits. No iris chafing was documented, and in all cases, a good distance was observed between the iris and the Sulcoflex Pseudophakic Supplementary IOL. A good distance was also observed between the supplementary IOL and the primary implant. No additive IOL exchange was necessary.

Conclusions:

The Sulcoflex IOL was well tolerated in all study eyes. Secondary implantation of the Sulcoflex IOL in the ciliary sulcus was a safe and predictable option for patients with pseudophakic refractive errors.

Financial Disclosure:

One or more of the authors gains financially from product or procedure presented, One or more of the authors travel has been funded, fully or partially, by a competing company

Back to previous